Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American Diabetes Association Scientific Sessions in Orlando, Florida, underscore significant weight loss and improved metabolic parameters among participants. The Phase 1, multiple ascending-dose study aimed to assess the safety, tolerability, pharmacokinetics, […]